BACKGROUND & AIMS:
Hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors are protective in mouse models of inflammatory bowel disease (IBD). Here, we investigated the therapeutic target(s) and mechanism(s) involved. METHODS: The effect of genetic deletion of individual HIF-prolyl hydroxylase (PHD) enzymes on the development of dextran sulphate sodium (DSS)-induced colitis was examined in mice. RESULTS: PHD1 Ϫ/Ϫ , but not PHD2 ϩ/Ϫ or PHD3 Ϫ/Ϫ , mice were less susceptible to the development of colitis than wild-type controls as determined by weight loss, disease activity, colon histology, neutrophil infiltration, and cytokine expression. Reduced susceptibility of PHD1 Ϫ/Ϫ mice to colitis was associated with increased density of colonic epithelial cells relative to wild-type controls, which was because of decreased levels of apoptosis that resulted in enhanced epithelial barrier function. Furthermore, with the use of cultured epithelial cells it was confirmed that hydroxylase inhibition reversed DSS-induced apoptosis and barrier dysfunction. Finally, PHD1 levels were increased with disease severity in intestinal tissue from patients with IBD and in colonic tissues from DSS-treated mice. CON-CLUSIONS: These results imply a role for PHD1 as a positive regulator of intestinal epithelial cell apoptosis in the inflamed colon. Genetic loss of PHD1 is protective against colitis through decreased epithelial cell apoptosis and consequent enhancement of intestinal epithelial barrier function. Thus, targeted PHD1 inhibition may represent a new therapeutic approach in IBD.
Keywords: Colitis; Hydroxylase; Apoptosis; Hypoxia. P rolyl hydroxylases (PHDs) are members of a large family of dioxygenases, a subset of which play a key role in intracellular oxygen-sensing and signaling responses during hypoxia, primarily by the regulation of the stability of the hypoxia inducible factor (HIF). [1] [2] [3] [4] Three PHD enzymes that confer oxygen sensitivity to the HIF pathway have been described (PHD1-3). 5, 6 Although these isoforms share similar biochemical characteristics, they have distinct tissue-specific expression profiles and, as well as regulating HIF, can also affect prosurvival signaling pathways, including nuclear factor B. 1, [7] [8] [9] [10] PHDs mediate their effects on HIF through (oxygendependent) hydroxylation of key proline residues on the oxygen-dependent degradation domain of HIF␣ subunits. When hydroxylated at these sites, HIF␣ becomes a target for ubiquitylation by the von Hipple Lindau E3 ubiquitin ligase leading to HIF␣ ubiquitination and degradation. The specific targets for PHDs in the NF-B pathway remain to be determined, although IKK␣ and IKK␤ contain surface-expressed consensus sites in their regulatory domains. 11 PHDs play a central role in the adaptive response to hypoxia through activation of these pathways with the subsequent expression of genes promoting cell survival, erythropoiesis, angiogenesis, and metabolism. As such, PHDs may be an effective target for therapeutic manipulation. 1, 12 It has recently become clear that hydroxylase activity can affect the development of inflammation and that hydroxylase inhibitors may represent a novel therapeutic approach in chronic inflammatory disease. 12, 13 Inflammatory bowel disease (IBD) is a genetically heterogenous, chronic inflammatory condition with severe pathology and limited therapeutic options. 14 -16 Although the underlying causes of IBD remain largely undefined, the fundamental defect involves a loss of intestinal epithelial barrier function. We and others have shown that pan-hydroxylase inhibitors such as dimethyloxalylglycine (DMOG) have a protective effect in murine models of colitis and thus represent a potential new therapeutic approach. 17, 18 However, those studies did not identify which hydroxylase isoforms or effector pathways are involved.
Mice lacking individual PHD enzymes have distinct phenotypes. PHD1 Ϫ/Ϫ mice show a reprogrammed basal metabolic profile that decreases muscle performance in healthy tissue but provides acute protection in muscle and liver ischemia. 19, 20 PHD2 Ϫ/Ϫ mice are embryonic lethal with a massive vascular defect during embryogenesis, 21 whereas heterozygous ( ϩ/Ϫ ) mice show enhanced tumor angiogenesis but decreased metastatic events through what has been termed "endothelial normalization." 22, 23 PHD3 Ϫ/Ϫ mice have reduced neuronal apoptosis, abnormal sympathoadrenal development, and reduced blood pressure. 24 The diverse phenotypes in mice with different PHD gene deletions strongly suggest that there are distinct isoform-specific functions for the various PHD enzymes in vivo.
To develop our understanding of the mechanisms of protection of pan-hydroxylase inhibitors in colitis, we investigated disease development in PHD1-, PHD2-, and PHD3-deficient mice exposed to dextran sulphate sodium (DSS) in their drinking water to induce colitis. We found that PHD1 Ϫ/Ϫ , but not PHD2 ϩ/Ϫ or PHD3 Ϫ/Ϫ , mice, were selectively protected against the development of colitis. This protection was associated with enhanced intestinal epithelial barrier function which was due to diminished epithelial cell apoptosis. These data implicate a positive role for PHD1 in the regulation of intestinal epithelial cell apoptosis during intestinal inflammation and strengthen the case for the development of PHD1specific inhibitors targeted to intestinal epithelial cells as a new therapeutic approach in the treatment of IBD.
Materials and Methods Animals
PHD1 Ϫ/Ϫ , PHD2 Ϫ/ϩ , and PHD3 Ϫ/Ϫ mice against a mixed background strain of Swiss/129, which were used for these experiments have been previously described. 19, 23, 24 None of the PHD knockout mice showed differential weight gain compared with wild-type mice.
DSS Colitis Model
The DSS model of colitis was used as described previously. 17 Briefly, acute disease was induced by the treatment of mice with 5% DSS in their drinking water for Յ6 days. The disease activity index was determined according to the parameters outlined in Supplementary  Table 1 . 25, 26 On termination of the experiment, mice were killed by cervical dislocation, and colonic tissues were dissected for further analysis. All procedures described were approved by the relevant institutional Animal Research Ethics Committee.
Assessment of Tissue Inflammation
Small (approximately 1 cm) sections of excised colonic tissue were fixed in 10% paraformaldehyde (pH, 7.4; phosphate-buffered saline [PBS] buffered) and embedded in paraffin. Sections (4 m) were cut and stained with H&E. Histologic assessment of colonic mucosae was carried out in a blinded fashion as described in Supplementary Table 2 . 26 To assay for markers of inflammation, colonic tissues were homogenized, and levels of tumor necrosis factor-␣, interleukin-1␤ (IL-1␤), IL-6, and myeloperoxidase were measured as described previously. 17
Western Blotting
Whole colon tissues were thawed, homogenized, sonicated in standard Western blotting lysis buffer, and vigorously stirred until a vortex formed before centrifugation at 12,000 rpm for 5 minutes. Supernatant was removed and normalized to 1 g/L and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described previously. 17 After transfer to nitrocellulose membranes, PHD1 was detected by Western blot with the use of an anti-PHD1 primary antibody (Novus Biologicals, Littleton, CO).
In Vivo Permeability Assay
Mice were exposed to 6 days of DSS treatment before oral administration of 0.6 mg/g of body weight fluorescein isothiocyanate (FITC)-labeled dextran (4 kDa) by standard oral gavage. Mice were killed 3.5 hours later, and blood was removed by cardiac puncture. Plasma was separated, and FITC levels in the plasma were determined by fluorometry. The distribution of FITCdextran in sectioned colonic tissue was determined by fluorescence microscopy.
In Vitro Permeability Assay
CaCo-2 epithelial cells (passage 19 -26) were seeded on uncoated 6.5-mm semipermeable (3.0-m pore) Transwell polycarbonate membranes (Costar, Cambridge MA). Monolayers were maintained for 4 -5 weeks before experimentation to ensure an efficient barrier and development of transepithelial electrical resistance (TEER). Cells were cotreated with DMOG 1 mmol/L (or dimethyl sulfoxide vehicle) and 4% DSS (wt/vol; in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum and penicillin/streptomycin) in the apical and basolateral compartments of the Transwell membrane. TEER values were obtained with the use of a REMS Autosampler (World Precision Instruments, Sarasota, FL) at the indicated time points. Values are indicative of triplicate wells per treatment for 4 independent passage numbers.
Immunohistochemistry
Sections (4 m) were cut from the paraffin blocks, deparaffinized with xylene, and rehydrated in a graded series of alcohols. For immunohistochemical staining, endogenous peroxidase activity was quenched with 3% hydroxen peroxide solution for 10 minutes. Antigen re-trieval was performed by immersing the slides in proteinase K solution (20 g/mL in 10 mmol/L Tris-HCl, pH 7.5) for 12 minutes. Sections were blocked with 5% goat serum for 1 hour at room temperature and then incubated overnight with primary antibody at 4°C in a humidified chamber. The primary antibodies used were rabbit anti-KI-67 (1:100 dilution; Abcam, Cambridge, United Kingdom), rabbit anti-cleaved caspase-3 (Asp175; 1:200 dilution; Cell Signaling Technology, Danvers, MA), and rabbit anti-cytokeratin 8 (1:100 dilution; Abcam). The slides were then treated with biotinylated goat antirabbit antibody (1:200 dilution; Vector Laboratories, Peterborough, United Kingdom). ABC immunodetection (VECTASTAIN Elite ABC Kit; Vector Laboratories) was used to detect cleaved caspase 3 and KI-67. The sections were developed with diaminobenzidine as a chromagen and counterstained with hematoxylin. Cytokeratin 8 was detected with avidin-conjugated Texas red (1:50 dilution; Merck Biosciences, Darmstadt, Germany) followed by nuclear counterstain with Hoechst 33342 dye. PBS/1% Tween solution was used to wash sections between steps. Colonic sections from 5 to 7 animals were stained for KI-67, cytokeratin 8, or cleaved caspase 3. In the case of KI-67 and cleaved caspase 3, for each section, three 200ϫ or 400ϫ fields, respectively, were randomly selected, and the number of positive cells per 100 enterocytes was quantified. All scoring was carried out in a blinded fashion.
Terminal Deoxynucleotidyl Transferase-Mediated Deoxyuridine Triphosphate Nick-End Labeling Stain
Cellular apoptosis was identified with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL; Fluorescein In Situ Cell Death Detection Kit; Roche Diagnostic, Mannheim, Germany). After de-waxing, rehydration and proteinase K antigen retrieval colon sections were incubated with the TUNEL reaction mix for 1 hour at 37°C in a humidified chamber. Sections were counterstained with Hoechst dye and analyzed with fluorescent microscopy. Colonic sections from 5 animals per group were TUNEL stained. For each section, three 400ϫ fields were randomly selected, and the number of positive cells per 100 enterocytes was quantified. All scoring was carried in a blinded fashion.
In Vitro Apoptosis Assay
CaCo-2 cells were treated with DMOG (1 mmol/L, 24 hours) or transfected with 50 nmol/L PHD1 short interfering RNA (siRNA) or control nontarget siRNA (Dharmacon, Lafayette, CO). Transfections were carried out with Lipofectamine 2000 (Invitrogen, Paisley, United Kingdom). After treatment, cells were treated with DSS (1%, 24 hours). The cells were harvested, resuspended in ice-cold PBS, and incubated with YO-PRO-1, Hoechst 33342, and propridium iodide (Vybrant Apoptosis Assay Kit #7; Invitrogen) according to the manufacturer's protocol. Flow cytometric analyses were carried out with the CyAn ADP analyser (Beckman Coulter, Fullerton, CA) and Summit 4.3 software. Cells were defined as living, early apoptotic, or late apoptotic/necrotic according to their relative dye uptake.
Statistical Analysis
Statistical comparisons were made by analysis of variance or Student t test. Values are expressed as mean Ϯ SEM for n individual experiments.
Results

PHD1-Deficient Mice Are Protected Against DSS-Induced Colitis
Previous studies have shown that treatment with pan-hydroxylase inhibitors is protective in DSS-induced colitis in mice. 17, 18 Those studies used broad-spectrum hydroxylase inhibitors such as DMOG because pharmacologic isoform-specific inhibitors are currently unavailable. To determine which PHD enzyme or multiple enzymes are responsible for the protective effects of panhydroxylase inhibition, we investigated the development of DSS-induced colitis in PHD1 Ϫ/Ϫ , PHD2 ϩ/Ϫ , and PHD3 Ϫ/Ϫ mice. We found that only PHD1 Ϫ/Ϫ mice were significantly protected from DSS-induced colitis as determined by weight loss ( Figure 1A ) and disease activity index measurements ( Figure 1B ). PHD1 Ϫ/Ϫ mice also had significantly attenuated histologic signs of inflammation compared with wild-type controls ( Figure 1C and D) . The reduced severity of DSS-induced colitis in PHD1 Ϫ/Ϫ mice was confirmed by the significantly lower levels of myeloperoxidase enzymatic activity, a marker of neutrophil infiltration, in the colons of PHD1 Ϫ/Ϫ mice relative to wild-type animals ( Figure 1E ). Furthermore, the levels of DSS-induced inflammatory cytokines, including IL-1␤, tumor necrosis factor-␣ and IL-6, were significantly lower in PHD 1 Ϫ/Ϫ mice than in wild-type controls ( Figure 1E ). In contrast, PHD2 ϩ/Ϫ and PHD3 Ϫ/Ϫ mice did not show attenuated DDS-induced inflammation in all parameters investigated (data not shown). Taken together, these data indicate that PHD1 Ϫ/Ϫ mice are selectively protected against the development of colitis.
Increased Enterocyte Density in PHD-Deficient Mice in Colitis
We next carried out high magnification (400ϫ) microscopic analysis of mucosal structure in wild-type and PHD1 Ϫ/Ϫ mice exposed to DSS. Increased intestinal epithelial cell density was observed in PHD1 Ϫ/Ϫ mice treated with DSS compared with wild-type controls (Figure 2A) . The insets in Figure 2A represent high magnification areas of intestinal epithelial cells showing increased epithelial density in colonic tissues derived from DSS-treated PHD1 Ϫ/Ϫ mice compared with wild-type mice. The enhanced epithelium was confirmed by epithe-lial-specific cytokeratin staining in colonic tissues ( Figure  2B ), which shows decreased ulceration in DSS-treated PHD1 Ϫ/Ϫ mice compared with wild-type controls. Collectively, these data led us to hypothesize that the protective effects of PHD1 deficiency were due to enhanced epithelial barrier function as a result of increased intestinal epithelial cell density.
Enhanced Epithelial Barrier Function in PHD1 ؊/؊ Mice
To further address the effects of loss of PHD1 on the intestinal epithelial barrier, in vivo intestinal barrier function was measured in wild-type and PHD1 Ϫ/Ϫ mice exposed to DSS. Mice were given an oral dose of FITCdextran on the final day of DSS exposure, and 4 hours later FITC levels in the plasma were determined as a measure of intestinal permeability. Although DSS induced a characteristic increase in intestinal permeability as reflected by increased appearance of FITC in plasma, this was markedly diminished in PHD1 Ϫ/Ϫ mice ( Figure  3A ). Furthermore, fluorescent microscopic detection of FITC in colonic tissues from these animals showed retention of FITC at the epithelial barrier in PHD1 Ϫ/Ϫ mice, whereas in wild-type mice FITC had transcended the epithelial barrier ( Figure 3B ).
To test whether hydroxylase inhibition can directly affect epithelial barrier function, we next exposed cultured intestinal epithelial cells (CaCo-2), grown on permeable support inserts to increasing periods of DSS and measured barrier disruption by measuring TEER. Cells treated with the hydroxylase inhibitor DMOG showed reduced barrier dysfunction compared with cells treated with vehicle and DSS alone, indicating that hydroxylase inhibition in isolated enterocytes confers resistance to DSS-induced barrier dysfunction (Supplementary Figure  1) . Taken together, these data indicate that loss of PHD1 leads to enhanced epithelial barrier function in colitis.
Decreased Enterocyte Apoptosis in PHD1 ؊/؊ Mice Exposed to DSS
We next investigated whether the increase in enterocyte density (Figure 2 ) and enhanced barrier function ( Figure 3 ) observed in PHD1 Ϫ/Ϫ mice was due to decreased epithelial cell death or increased proliferation. Immunohistochemical KI67 staining (a marker of proliferating cells) was not different between wild-type and PHD1 Ϫ/Ϫ mice either with or without DSS treatment, indicating no difference in proliferation between groups ( Figure 4A ). We next investigated intestinal epithelial cell apoptosis with the use of both TUNEL staining and detection of cleaved caspase 3. Basal rates of apoptosis detected with both techniques were similar in PHD1 Ϫ/Ϫ and wild-type mice. However, PHD1 Ϫ/Ϫ mice exhibited a significantly lower degree of enterocyte apoptosis when exposed to DSS than did wild-type mice ( Figure 4B and C) . Collectively, these data indicate that PHD1 Ϫ/Ϫ mice are resistant to DSS-induced colitis because of barrier-protective effects associated with decreased enterocyte apoptosis.
To investigate whether PHD1 inhibition could directly affect epithelial apoptosis, cultured enterocytes were exposed to DSS in the presence and absence of the pan hydroxylase inhibitor DMOG or siRNA targeted to PHD1, and the induction of early and late apoptosis was measured. DMOG ( Figure 5A ) or PHD1 siRNA ( Figure  5B ) significantly inhibited DSS-induced apoptosis in isolated enterocytes, indicating a direct antiapoptotic effect of pharmacologic hydroxylase inhibition on epithelial cells. (A) Intestinal permeability was measured by the appearance of orally administered FITC-labeled dextran in plasma from wild-type and PHD1 Ϫ/Ϫ mice exposed to DSS (bars represent mean Ϯ SEM; *P Ͻ .5; n ϭ 6). (B) Fluorescence microscopy (100ϫ) of the intestinal mucosa from DSS-treated wild-type (WT) and PHD1 Ϫ/Ϫ mice exposed to orally administered FITC-labeled dextran shows FITC permeation into tissue is enhanced in wild-type animals treated with DSS compared with PHD1 Ϫ/Ϫ animals whereby FITC-dextran is retained at the epithelium (scale bar ϭ 100 m) L, lumen.
PHD1 Expression Is Correlated With Disease Severity in Patients With IBD
Having identified PHD1 as a potential target for pharmacologic intervention in IBD, we next examined the expression of PHD1 in intestinal tissue taken from patients undergoing restorative proctocolectomy for surgical treatment of IBD. Intestinal tissues from patients with IBD were independently scored by 2 clinical pathologists and categorized for histopathologic grade of inflammation according to the Truelove and Richards scale 27 (grade 0, no inflammation; grade 1, chronic inactive inflammation [increased content of mononuclear cells within the mucosal lamina propria]; grade 2, mild active inflammation [plus few circumscript foci with neutrophilic intraepithelial infiltrates/cryptitis or single crypt abscesses]; grade 3, moderate active inflammation [plus several foci with neutrophilic intraepithelial infiltrates/cryptitis or crypt abscesses]). Semiquantitative analysis of immunoblots showed significantly higher expression of PHD1 protein in colon samples that displayed active mucosal inflammation ( Figure 6A and B) . Indeed, PHD1 was relatively overexpressed in 100% of tissue samples displaying high inflammatory activity (Truelove and Richards score 2-3). By contrast, relative overexpression of PHD1 was only observed in 33% of samples with inactive inflammation (Truelove and Richards score 0 -1). This difference was significant when applying the Fisher's exact test (P ϭ .015; n ϭ 8). Similarly, colonic tissue from mice showed increased PHD1 expression after DSS exposure ( Supplementary Figure 2) . In summary, although PHD deficiency or inhibition is associated with decreased disease activity, increased PHD expression is associated with disease severity. 
Discussion
A common feature of all IBD regardless of the underlying cause is the loss of intestinal epithelial barrier function because of excessive epithelial cell death, an event that allows the nonspecific movement of luminal antigenic material into the submucosa. 28 The resulting inflammatory response drives further barrier dysfunction and the symptoms associated with the disease, thus establishing a positive feed forward loop between developing inflammation and barrier dysfunction. The intestinal epithelial barrier relies heavily on the controlled turnover of intestinal epithelial cells, which originate from stem cells in the intestinal crypts and migrate to the top of the crypt or villus before undergoing apoptosis and being released into the intestinal lumen. The regulation of the intestinal epithelial cell turnover is a complex balance between epithelial proliferation and cell death in which stem cells play a key role. 29 In the physiologic state, intestinal epithelial cells have a relatively short life span, and their programmed cell death through apoptosis is a carefully controlled process that is probably critical for the maintenance of normal barrier function. 30 The regulatory factors that are responsible for the initiation of physiologic intestinal epithelial cell apoptosis remain to be fully elucidated; however, increased rates of apoptosis with resultant dysfunction of the intestinal epithelial barrier is central to the pathology of IBD. 31 Thus, therapies directed toward delaying or suppressing intestinal epithelial cell apoptosis may allow time for mucosal healing to occur in IBD and may thus represent a therapeutic approach.
We, and others, have demonstrated that pan hydroxylase inhibition is protective against the development of colitis in multiple models. 17, 18 In the current study, we find that PHD1 Ϫ/Ϫ mice selectively show a significant decrease in DSS-induced apoptosis, an event that we hypothesize to be linked to enhanced barrier function and subsequent protection against the development of colitis. This is supported by studies that investigated the link between hydroxylase activity and apoptosis in other model systems, which have shown an antiapoptotic effect of pharmacologic hydroxylase inhibition. [32] [33] [34] Hydroxylase inhibition affects multiple transcriptional pathways, including HIF and NF-B, both of which have been shown to be protective in epithelial cells during IBD. 35 HIF activates the expression of a range of factors, including intestinal trefoil factor, CD73, and the adenosine A2B receptor that have been shown to be barrier protective. 35 Furthermore, NF-B activation results in increased expression of antiapoptotic factors. 36 We have proposed that the combined effects of barrier protective and antiapoptotic gene expression in epithelial cells, which occurs by these pathways, underpin the effectiveness of pan-hydroxylase inhibitors in models of IBD. 35 In the current study, we have identified that PHD1 is the key target hydroxylase in mediating the protective effects of hydroxylase inhibitors in colitis and thus represents a likely therapeutic target for IBD. Importantly, because of the lethality of a homozygous PHD2 knockout mouse, we cannot rule out a possible role for a protective effect of complete PHD2 inhibition during colitis. Future studies will determine whether the protection afforded by hydroxylase inhibition is by activation of HIF, NF-B, or other transcriptional regulators. Increased PHD1 correlates with disease severity in patients with IBD, reflecting a positive relationship between the expression levels of PHD1 and disease severity. In a previous study, Robinson et al 18 demonstrated that PHD isoform mRNA expression levels in the intestinal mucosa were in the order PHD2 ϭ PHD3 Ͼ PHD1. Although the mRNA expression levels of PHD1 are lowest in noninflamed tissue, we found that PHD1 levels were increased in inflamed tissues from patients with IBD, raising the intriguing possibility that increased PHD1 expression or activity may be contributing to disease progression through increasing epithelial cell apoptosis and reducing barrier function. In summary, we propose that, as a positive regulator of intestinal epithelial cell apoptosis in colitis, PHD1 represents a new therapeutic target in the treatment of inflammatory bowel disease.
